These inflammatory biomarkers, including CRP, IL-6, and TNF-α, are associated with neuroinflammation in AD, which enhances neuronal loss and cognitive impairment. It may be therapeutic to target these markers in the hopes of diminishing inflammation and impeding the advancement of the disease. This evidence concerns the gene TNF and Cognitive impairment.